We hypothesized that elevated hepatic glucose output (HGO) may occur in children with cystic fibrosis (CF) as an early sign of declining insulin secretion and that tolbutamide therapy would correct the defect. We studied eight glucose-tolerant CF patients (X ::!:: SD, 9.1 ::!:: 1.9 y) and five healthy controls (9.0 ::!:: 1.6 y). Fasting glucose, insulin, and insulin-connecting peptide concentrations were not different in the CF and control subjects; however, meal stimulation tests in the CF patients suggested that insulin secretion was defective in the fed state. HGO (mg-kg-1 body weight· min-I) was 26% higher in the CF patients (4.2 ::!:: 0.7 versus 3.1 ::!:: 0.6 in HC) (p = 0.016). When normalized for fat-free mass (mg -kg fat-free masal : min-I), HGO was 27% higher in CF (4.9 ::!:: 0.8 versus 3.8 ::!:: 0.5) (p = 0.015). However, when expressed as a function of resting energy expenditure (mg· kcal-I), HGO was not significantly different in CF (121 ::!:: 22) versus healthy controls (116 ::!:: 30). In seven of the CF group, HGO was re-assessed after a 2-h glucose infusion at a rate of 0.90 ::!:: 0.02 mg : kg-I. min-I . HGO was suppressed (p < 0.05) by an amount equal to 103 ::!:: 18% of the glucose infusion rate.
Many patients with CF have secondary complications of glucose intolerance, the incidence of which appears to increase with age (1) (2) (3) (4) . In a retrospective study of clinical data, Lanng et al. (5) compared CF patients who developed diabetes mellitus with control CF patients during the previous 6-y period. Those who had developed diabetes demonstrated impaired weight gain (and lower body mass index), worsening pulmonary function, and impaired exocrine pancreatic function from 1 to 4.5 y before the diagnosis of diabetes.
We (6) previously showed that tolbutamide therapy in nondiabetic children with CF is associated with improved growth and accretion of fat-free mass in comparison to a baseline observation period. Subsequently, we found that feeding did not suppress whole body proteolysis in children with CF, suggesting that impaired insulin secretion or insulin action Finally, in five CF patients, HGO was re-measured after 2 wk of oral therapy with tolbutamide (750 mg/d). Tolbutamide did not affect HGO (fasting or during the glucose infusion). In conclusion, fasting HGO was elevated in the CF patients in proportion to energy expenditure. (Pediatr Res 37: 600-605, 1995) Abbreviations CF, cystic fibrosis C peptide, insulin-connecting peptide D 2 0 , deuterium oxide F DG, the rate of administration of glucose tracer GCRC, NIH General Clinical Research Center HGO, hepatic glucose output IE DG, isotopic enrichment of glucose produced by deuterated glucose tracer Ra DG, rate of appearance of glucose measured using deuterated glucose Vco 2 , net rate of excretion of CO 2 (equated to rate of CO 2 production) might limit accretion of protein in this patient population (7) . We speculated that impaired nutritional status could limit host defense and pulmonary function resulting in increased infection and worsening prognosis.
As part of a therapeutic trial, we examined the effect of tolbutamide on HGO and its suppressibility by i.v. glucose infusion and also compared fasting HGO in the patients with that in healthy control children. This report describes the results of this study.
METHODS
Subjects. Eight, nondiabetic, prepubertal, CF patients requiring oral pancreatic enzyme supplementation were recruited for this study (Table 1 ). In addition, we recruited five healthy controls. To participate, subjects had to be free of overt infection, afebrile, and off antibiotics for a minimum of 10 days before being studied. In addition, the CF patients had to be glucose-tolerant as evidenced by plasma glucose concentrations 2 h after a standard meal (vide infra) (6) . The procedures were explained to the subjects and their parents, and informed t Ther e were no significant differences between groups in age, height, weight, or percent IBW.
consent was obtained befor e particip ation in the study. The study was appro ved by the institutions ' committees for research on human subj ects. To determine the degree to which HGO in the fasting state was abnormal in the CF patient s, we also assessed glucose turnover in five healthy, prepubertal children (8) .
Experimental design. Four days before the glucose tracer study, total body water was estimated using the procedure noted below.
As part of our ove rall study which includ ed measurements of leucine oxidation in the fed and fasted states, subje cts were admitted to the General Clinical Research Center (GCRC) for 4 d. During the first 3 d of admission, subjects were provided a diet that match ed the energy intake of the typical diet based on 4-d diet records kept by the subjects. Subjects began fasting at 2100 h on d 3 and continued to fast until 1400 h on d 4. During the period, 0900-0950 h on d 4, the Vco, was measured using the Dougl as bag technique (descr ibed below). A catheter for blood drawing was insert ed into a peripheral vein of an upper extremity on d 3; after warmin g the vein, a blood sample was drawn from this catheter at 0950 h on d 4 for assessment of background enrichment of plasma glucos e. A second catheter in the opposite arm was also inserted on d 3 and used for isotope and gluco se infusion. Beginning at 1000 h on d 4, subjects received a prime constant infusion of [6,6- dz]-glucose (99%, MSD Isotope; Quebec, Canada; prime: 18 /Lmol ' kg body we ight" ; infusion: 0.22 /Lmol' kg-1 • min ? or 0.04 mg-kg-1 . min-1). After 80 min of infusion, four blood samples were drawn at 10-min interv als. Samples wer e centrifuged, and plasma was stored at -80°C until analysis of the enrichment of plasma glucose . In addition, plasma samples obtain ed during the last 40 min of the fasting tracer infusion were pooled and analyz ed for glucose, insuli n, and C peptide concen trations . At the end of 2 h, in the CF patients only, while the deuterated glucose infusion continued, an i.v. infusion of unlabeled glucose at an approximate rate of 1.0 mg : kg-1 • min-1 (5.6 /Lmol . kg . min -1) was administered to determine the suppressibility of the hepatic glucose output by glucose (9) . Blood samples were collected during the period 80-120 min of the dual infusion, again at lO-min intervals .
Aft er the compl etion of these fasting studies, the subje cts were allowed to eat, and then they were disch arged from the GCRC. However, five of the CF patients then began daily therapy with tolbutamide (750 mg/da y) for 2 wk after which the tracer studies were repeated according to the protocol just described.
Health y controls were admitted to the GCR C overnight and studied the next morning at 1000 h, after a 13-h fast.
Estimation of HGO. The Ra DG was calculated as follows (10):
wh ere F DG is the rate of administration of [6,6- dz]-glucose (mol ar units, corrected for enrichment) and IE DG is the isotopic enrichment of plasma glucose (expressed as fractional abund ance, mole s fraction excess). For the data reported here , the rate of appearance of gluco se was not corrected for the infusion rate of tracer, because there is evidence that even trac er doses of glucose will suppress endogenous glucose produ ction proportionately (11) . However, since there is controversy about the correct approach, we also repeat ed our calculations using such a correction (11) . There was a slightly greater relative increase in HGO in the CF patients using this correction (also see "Results"), but the data describing the effects of the glucose infusions and tolbutamide therapy were virtually identical using this appro ach. HGO was equated to Ra DG in the fasting state. During the glucose infusion , HGO was calculated by subtracting the rate of gluco se infusion from Ra DG .
The HGO data in the resting, baseline state in the two groups were comp ared when expressed per unit body weight and per unit fat-free mass, to correct for differences in body composition between the two groups. Several (12) (13) (14) (15) but not all (16) studies suggest that resting energy expenditure is abnormally elevated in CF patients. Because energy expenditure per unit cell then may be greater in children with CF compared with healthy children, we also compared fasting HGO data in the two groups as a function of resting energy expenditure estimated from the Vco-, GC/MS. The enrichment of plasma glucose (IE DG) and the tracer was analyzed using the pentacetate derivative and electron impact, gas chromatography/mass spectrometry GC/MS (17) Measurement of body composition. Fat-free mass and percent of body fat were estimated from measurements of total body water determined using either 180-water or DzO. After collecting a baseline urine sample (and emptying the bladder), subjects ingested either 0.3 g 180-water' kg body weighC 1 (or about 15 mmol-kg body weightI " ) (11.2%, MSD Isotope, Ontario, Canada) or 0.04 g D 20' kg-1 body weight (or about 2 mmol-kg weight'T") (99 %, MSD Isotope, Ontario, Canada). Urine samples were collected 3 and 4 h after tracer ingestion; the 4-h sample was used to determine the equilibrium enrichment of the body water. To determine enrichment of 180 in the urine, samples were equilibrated with CO 2 for 72 h, and the gas sample was then cryogenically purified and then analyzed by gas isotope ratio mass spectrometry (Delta E, Finnigan MAT, Bremen, Germany) (17) . D 20 enrichment was determined also by gas isotope ratio mass spectrometry using the zinc reduction method (19) . Total body water was calculated using the deuterium or 180 labeled isotopes after correction for isotopic fractionation (20, 21 ). An adjustment was made in the calculations for the fact that the D 20 space is about 3% larger than the H 2 180 space (17) . Using an estimate of the hydration of fat-free mass that was appropriate for sex, ethnicity, and maturation level (22) , total body water was converted to fatfree weight.
Measurement of the Vco z and estimation of energy expenditure. Using a face mouthpiece, 2-way non-re-breathing valve, and Douglas bags, expired air was collected for two, 6-min periods in the fed and fasted state. Subjects, at rest and in a reclining position, were briefly accustomed to the apparatus before actually collecting expired air samples. A 60-ml aliquot was drawn from each bag and set aside for subsequent analysis of the fractional concentration of CO 2 , measured with a Beckman Industrial CO 2 analyzer (Beckman Instruments, Fullerton, CA). The volume of the timed collection was measured with a Rayfield gas meter (Rayfield System, Chicago, IL), which had been validated against a Tissot spirometer. Assuming a room air CO 2 concentration of 0.03 %, Vco 2 was then calculated. Energy expenditure was estimated by standard equations (23) assuming a respiratory quotient of 0.834 (12) .
Measurement ofplasma and tracer concentrations of glucose, plasma concentrations of insulin and C peptide, and meal stimulation test.
Glucose concentration was measured using a YSI Glucose Analyzer (model 27, Yellow Springs Instrument Co., Yellow Springs, OH). Plasma insulin and C peptide were measured by radioimmunoassay using previously described methodology (24) . The assay sensitivity for insulin was approximately 2.5 /-LU' ml-1 (or 17.9 pmol-L-1) and the assay sensitivity for C peptide was about 0.1 ng : ml-1 (or 0.033' nmol-L-1).
In the CF patients only, a meal stimulation test was conducted as previously described (6) as part of our initial screening of the subjects. The data were compared with laboratory control data from previous studies in nine healthy, prepubertal children not involved with the tracer studies.
Statistical design. Data are presented as mean ± SD. A two-sample t test was used to determine whether HGO differed between CF patients and healthy controls. A paired t test was used to evaluate the suppressibility of HGO when unlabeled glucose was infused and to assess the effect of tolbutamide on HGO. A probability level of 0.05 was selected for statistical significance.
RESULTS
Individual CF patient characteristics are presented in Table  1 . The mean ages of the CF patients and healthy controls were in the controls (p > 0.05 for both). There also were no differences in the means of the individual ratios for insulin/C peptide between the CF patients (3.4 ± 2.7) and controls (3.1 ± 1.5) or in the means for the fasting glucose/insulin concentration ratio between CF patients (0.025 ± 0.015) and controls (0.032 ± 0.013) .
During the meal stimulation test, the mean area under the curve for glucose was not significantly different from that derived from the previously studied, laboratory controls CF patients was below the control mean, and in six of seven was greater than 1 SD below the mean (Fig. 1) . The mean area under the curve for C peptide was 60% of the control mean (p > 0.05), and in four of seven was greater than 1 SD below the control mean (Fig. 2) .
HGO (mg-kg body weightT> min -lor /-Lmol· kg body weight-1. min') was 26% greater in CF patients (4.2 ± 0.7 or 23.3 ± 3.8) than in healthy controls (3.1 ± 0.6 or 17.2 ± 3.3) (p < 0.05) (Fig. 3) ; factoring in the tracer infusion in the wk (750 mg/d) (in 5 subjects only) had no effect on either the fasting rate of HGO or the degree of suppression by glucose (Table 2 and Fig. 4 ).
• Fasting _ IV Glucose As can be seen from Figure 4 , oral tolbutamide had no effect on the elevated rate of hepatic glucose production in the fasting state and had no effect on the suppression of hepatic glucose output by glucose infusion. The latter observation is not surprising considering our observation that, even in the baseline condition, a glucose infusion of approxi mately 1 mg : kg-I. min-I suppressed HGO to an equivalent degree. In view of our earlier observations that tolbutamide therapy .s 1.50
:. o 0.50 HGO calculation resulted in a 38% increase in the CF patients (p = 0.01).
The CF patients seemed to be leaner than the controls although not to a statistically significant extent; percent of body fat was 14 ± 6% in the CF patients versus 20 ± 8% in controls (p < 0.05). However, when expressed as mg : kg fat free mass-I. min-I (or /Lmol "kg fat-free mass-I" min-I) HGO was 27% higher in the CF group compared to the controls (4.9 ± 0.8 versus 3.8 ± 0.5) (or 27.2 ± 4.4 versus 21.1 ± 2.8) (p = 0.015) (Fig . 3) . Mean resting ene rgy exp enditure (kcal-kg-I" min-I) was 29% higher but not significantly different in the CF patients (0.036 ± 0.005) compared with the healthy controls (0.028 ± 0.013). However, when expressed per unit energy expenditure (mg : kcal-1 or umol-kcal"), HGO in CF patients (121 ± 22 or 672 ± 122) was not statistically different from the controls (116 ± 30 or 644 ± 167).
As noted above, in seven of the CF patients, the glucose tracer infusion was continued for an additional 120 min during which a continuous infusion of unlabeled glucose also was administered (X ± SD, 0.90 ± 0.02 mg -kg-I. min-lor 5.0 ± 0.11 /Lmol' kg-I. min-I). HGO was suppressed by an amount approximately equal (103 ± 18%) to the glucose infusion (Fig. 4 and Table 2 ). Oral tolbutamide therapy for 2 seemed to enhance accret ion of fat-free mass in children with CF (6), the present results suggest that the putative effect of this drug on growt h is not related to its possible inhibitory effects on hepatic gluconeogenesis (25) . This view coincides with recent thinking that an accelerated rate of gluconeogenesis does not increase whole body proteo lysis in trauma (26, 27) . Despite normal clinical tolerance of glucose and normal fasting concentration of glucose , insulin, and C peptide, the CF patients demonstrated higher rates of endogenous glucose production compared with normal children. Because we observed on the basis of the C peptide concentra tion, no evidence for decreased insulin secretion in the fasting state, we wondered whether the CF patients were demonstrating hepatic insulin resistance. There is evidence in the literature for both decreased (3) and increased (4) periphera l sensitivity of glucose metabolism to insulin in CF patients , but, to our knowledge, hepatic glucose output has not been studied , at least in prepubertal children with the disease. However insulin/C peptide ratios also were not different in the two groups (implying no difference in hepatic insulin extraction), and the glucose infusion was associa ted with an equivalent suppression of HGO, sugges ting norma l hepatic sensitivity to insulin (although glucose not insulin was infused) (9). Thus, there was no evidence for hepatic insulin resistance. Moreover, although we have not formally studied peripheral insulin sensitivity in these patients , it is of interest that insulin to glucose ratios were not different from the healthy control subjects .
Normalizing the HGO data for the fat-free mass did not appreciab ly reduce the percentage difference observ ed between CF patients and controls, but if the intensity of energy metabolism per unit cell was greater in the CF patients, then elevate d HGO would seem to be an adaptive respons e to the need for greater glucose uptake. In fact, there is some evidence that interindividual differences in insulin-mediated glucose disposa l can best be explained or normalized by using metabo lic rate (28) . In our study, mean resting energy expenditure was not elevated to a statistically significant degree in the CF patients (despite a 29% highe r rate), but when HGO (mg/min) was normalized for resting energy expenditure (kcal/min), a difference in HGO between CF patients and controls was no longer identified. Thus , elevated glucose turnover seems to have been the appropriate response to increased glucose, and perhaps energy, needs. Estimation of energy expenditure was based on an assumed respiratory quotient, but this is unlikely to have caused much error in this value (29) .
Although our CF patients were afebrile and clinically stable, it is quite plausible that subclinical or incipient inflammation of the lungs also may have contributed to hormon al stress that would lead to elevated HGO. Howev er, counter-regulatory hormone secretion was not assessed in this study; therefore, we are uncertain about the hormonal chain of events that "permitted" HGO to increase above normal and thus, presumably, meet elevated glucose and energy needs.
In summary, glucose tolerant CF patients, with abnormally diminis hed insulin secretion in the fed state, demonstrated an increase in fasting, steady-state HGO that was balance d by increased glucose uptake and proport ional to an increase in energy expenditure. HGO was apparently normally regulated by exogeno us glucose intake (via insulin presumably). Future exploration of the mechanism respons ible for the observed increase in HGO might include detailed study of counter regulatory hormone levels and peripheral insulin sensitivity.
